Congressman Bill Johnson (R-OH) cautions Americans about misaligned healthcare priorities.
Rep. Bill Johnson (R-OH) questioned Pharma’s talking points this week in a E&C markup, saying “we need to be careful about inserting the federal government into even more of the American people’s healthcare decisions especially in a private market.
We applaud him for taking a stand against Big Pharma interests. It’s strange how some Republicans are fanatical about targeting PBMs. The opposition to PBMs seems to rely heavily on talking points drafted by Big Pharma companies and their lobbyists in Congress.
Although PBMs have received increased scrutiny over the years on topics ranging from transparency to market competition, they are often the only buffer between Americans and Big Pharma’s abusive drug prices.
